Your session is about to expire
← Back to Search
Olaparib for Fallopian Tube Serous Adenocarcinoma
Study Summary
This trial studies the side effects and best dose of two drugs, olaparib and onalespib, when given together to treat patients with metastatic or unresectable solid tumors, or ovarian, fallopian tube, primary peritoneal, or triple-negative breast cancer that has come back.
- Fallopian Tube Serous Adenocarcinoma
- Cancer
- Peritoneal Serous Adenocarcinoma
- Breast Cancer
- Fallopian Tube Carcinoma
- Ovarian Cancer
- Peritoneal Carcinoma
- Ovarian Serous Adenocarcinoma
- Solid Tumors
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 3 trial • 154 Patients • NCT02184195Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
To what maladies is Olaparib commonly prescribed?
"Olaparib has been clinically proven to treat advance directives, malignant neoplasms of the ovary, and primary peritoneal cancer."
Is this innovative clinical trial the first of its kind?
"Since 2005, the pharmaceutical company AstraZeneca has been researching Olaparib. After a successful Phase 1 trial involving 98 patients in that same year, there are 191 studies active across 60 different nations and 1469 cities."
Could you please detail the geographical distribution of this medical study in North America?
"This medical trial is conducted at 8 sites across the United States. These locations are based in Jacksonville, Scottsdale and Phoenix as well as additional cities. To reduce travel burdens, it's recommended to select the nearest clinic if you intend to participate."
What is the size of the sample population for this research project?
"Unfortunately, this trial is not accepting applications at the moment. The listing was first published on May 19th 2017 and its details were most recently revised on December 9 2021. Should you be interested in other opportunities, there are 803 clinical trials enrolling patients with unresectable high grade fallopian tube serous adenocarcinoma as well as 191 studies that have Olaparib treatments available for participants."
What adverse effects can arise from the use of Olaparib?
"Olaparib's safety is still largely unknown, engendering a score of 1. This drug is currently in its first phase of clinical trials, and data on both efficacy and safety are limited."
Has Olaparib been subject to any prior investigations?
"Presently, 191 clinical trials are evaluating Olaparib's efficacy with 27 of those in the late-stage Phase 3. Despite many studies occurring within Houston, Texas; there is a total of 9265 research sites disseminated throughout the world studying Olaparib."
Is this experiment currently accepting participants?
"This trial has ceased to recruit any further participants. It was published on May 19th 2017 and had its last edit made December 9th 2021. Presently, there are 8003 studies open for people with unresectable high grade fallopian tube serous adenocarcinoma and 191 clinical trials utilising Olaparib actively searching for enrollees."
Share this study with friends
Copy Link
Messenger